EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

De‐Escalation Treatment Strategies From Natalizumab in Patients With Relapsing Multiple Sclerosis in Austria

Michael Guger iD, Christian Enzinger, Bettina Heschl, Franziska Di Pauli iD, Christane Gradl iD, Stefan Kalcher, Erich Kvas, Thomas Berger, Austrian MS Treatment Registry (AMSTR)

European Journal of Neurology · 2025

DOI: 10.1111/ene.70282 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Michael Guger und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Pyhrn-Eisenwurzen Hospital Steyr, Steyr, Austria. Hauptthemen laut MEDLINE: Natalizumab, Multiple Sclerosis, Relapsing-Remitting, Immunologic Factors, Immunosuppressive Agents. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharma Austria, Merck Austria, Sanofi Austria.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study aims to assess the efficacy of de‐escalating from natalizumab (NTZ) to cladribine (CLAD), dimethyl fumarate (DMF), fingolimod (FTY), ponesimod (PONE), siponimod (SIPO) and teriflunomide (TERI). Material and Methods We analyzed data from 388 patients in the Austrian MS Treatment Registry who initiated NTZ treatment and remained on therapy for at least 3 months before switching to one of the moderately effective therapies within 1 year. Patients were required to remain on the de‐escalation therapy for at least 3 months.

Results

Over a mean treatment duration of 42 months, the estimated ARR (annualized relapse rate) was 0.22 for highly effective therapy and 0.36 for de‐escalation therapies over 61 months ( p = 0.009). EDSS scores increased significantly from 2.8 to 3.1 during de‐escalation ( p < 0.001). Relapse probability during the treatment gap varied by interval: 14 patients (5.2%) in the < 3 months group, 14 patients (15.7%) in the 3–6 months group, and 13 patients (39.4%) in the 6–12 months group ( p < 0.001). Male sex, lower baseline ARR (prior to the initiation of hDMT) and during transition, older age, shorter disease duration, and lower EDSS scores at both baseline and post‐transition were significantly associated with a reduced risk of relapse and longer time to first relapse following de‐escalation.

Conclusions

Our findings reveal an increased risk of relapses and EDSS worsening following de‐escalation from NTZ. Additionally, relapse probability and EDSS progression were influenced by ARR during transition and EDSS scores at the end of the transition period.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NatalizumabMultiple Sclerosis, Relapsing-RemittingImmunologic FactorsImmunosuppressive AgentsHumansMaleFemaleAustriaAdultMiddle AgedRegistriesTreatment OutcomeNitrilesRecurrenceToluidines

Stichwörter der Autor:innen

de‐escalationefficacymultiple sclerosisnatalizumabreal‐worldregistry

Substanzen

NatalizumabImmunologic FactorsImmunosuppressive AgentsNitrilesToluidines

Autor:innen und Institutionen

  • Department of Neurology, Pyhrn-Eisenwurzen Hospital Steyr, Steyr, Austria.
  • Medical Faculty, Johannes Kepler University Linz, Linz, Austria.
  • Department of Neurology, Medical University of Graz, Graz, Austria.
  • Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
  • Department of Neurology, Medical University of St. Pölten, St. Pölten, Austria.
  • Hermesoft, Data Management, Graz, Austria.

ORCID-Profile: Michael Guger, Franziska Di Pauli, Christane Gradl

Förderung

  • Novartis Pharma Austria
  • Merck Austria
  • Sanofi Austria
  • Roche Austria
  • Biogen Austria
  • Janssen-Cilag Austria
  • Bristol Myers Squibb Austria

Zitieren

APA

Guger, M., Enzinger, C., Heschl, B., Di Pauli, F., Gradl, C., Kalcher, S., Kvas, E., Berger, T., & Austrian MS Treatment Registry (AMSTR) (2025). De‐Escalation Treatment Strategies From Natalizumab in Patients With Relapsing Multiple Sclerosis in Austria. European Journal of Neurology. https://doi.org/10.1111/ene.70282

Vancouver

Guger M, Enzinger C, Heschl B, Di Pauli F, Gradl C, Kalcher S, et al. De‐Escalation Treatment Strategies From Natalizumab in Patients With Relapsing Multiple Sclerosis in Austria. European Journal of Neurology. 2025. doi:10.1111/ene.70282

BibTeX
@article{Guger2025,
  author = {Guger, Michael and Enzinger, Christian and Heschl, Bettina and Di Pauli, Franziska and Gradl, Christane and Kalcher, Stefan and Kvas, Erich and Berger, Thomas and Austrian MS Treatment Registry (AMSTR), Austrian MS Treatment Registry (AMSTR)},
  title = {De‐Escalation Treatment Strategies From Natalizumab in Patients With Relapsing Multiple Sclerosis in Austria},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.70282}
}
Kostenlos starten →